(Q3)Dec 31, 2022 | (Q2)Sep 30, 2022 | (Q1)Jun 30, 2022 | (FY)Mar 31, 2022 | (Q4)Mar 31, 2022 | (Q3)Dec 31, 2021 | (Q2)Sep 30, 2021 | (Q1)Jun 30, 2021 | (FY)Mar 31, 2021 | (Q4)Mar 31, 2021 | |
---|---|---|---|---|---|---|---|---|---|---|
Operating Cash Flow (Indirect Method) | ||||||||||
Cash flow from continuing operating activities | -168.76%-66.65K | 79.56%-70.62K | 90.72%-32.32K | 97.46%-176.95K | 156.85%419.81K | 104.18%96.94K | -55.12%-345.49K | 90.56%-348.2K | 73.95%-6.97M | 78.89%-738.44K |
Net income from continuing operations | 57.61%-1.36M | -42.46%-2.33M | 24.14%-1.51M | 69.41%-12.93M | 72.54%-6.1M | 71.47%-3.2M | 51.95%-1.64M | 63.29%-1.99M | -12.96%-42.27M | -18.53%-22.22M |
Operating gains losses | ---- | ---- | ---- | -1.09%667.51K | 214.53%649.64K | -99.93%270 | -1,519.48%-67.68K | -90.34%85.27K | 47.60%674.85K | -2,340.93%-567.22K |
Depreciation and amortization | -94.31%66.63K | 200.42%453.69K | 0.41%453.61K | -20.49%1.71M | 21.75%542.78K | 134.18%1.17M | -174.72%-451.77K | -25.36%451.77K | -3.13%2.16M | -28.93%445.83K |
Asset impairment expenditure | ---- | ---- | ---- | -81.13%4.64M | -75.93%4.19M | ---- | ---- | ---- | 138.84%24.6M | 68.82%17.39M |
Remuneration paid in stock | -87.43%1.52K | -85.46%2.47K | 223.67%4.57K | -97.62%37.46K | -99.35%6.94K | -96.66%12.1K | 123.19%17.01K | -99.35%1.41K | -38.80%1.57M | 165.95%1.07M |
Other non cashItems | 106.08%22.6K | -97.75%15.13K | -266.65%-238.53K | -113.04%-429.95K | -145.77%-665.48K | -153.43%-371.75K | 25.68%672.34K | -110.62%-65.06K | 424.84%3.3M | 261.12%1.45M |
Change In working capital | -56.23%902.81K | 64.89%1.79M | 7.54%1.26M | 104.25%6.12M | 6.24%1.8M | 928.67%2.06M | -48.85%1.09M | 304.55%1.17M | 154.40%3M | -51.46%1.7M |
-Change in receivables | 13.92%496.91K | -5.86%-292.82K | -148.39%-565.38K | 13.79%377.11K | -66.41%445.13K | 179.62%436.2K | 37.69%-276.6K | -10,255.87%-227.62K | 151.16%331.41K | -12.04%1.33M |
-Change in inventory | -1,192.33%-1.04M | -30.90%144.65K | -39.93%-215.07K | -934.98%-571.78K | -152.69%-723.03K | 106.58%95.6K | 55.80%209.35K | -1,140.79%-153.7K | 100.48%68.48K | 169.01%1.37M |
-Change in prepaid assets | 166.99%73.48K | -201.01%-187.88K | 44.48%-35.01K | -110.86%-102.62K | -53.95%132.54K | -126.78%-109.7K | -125.00%-62.42K | -2,583.15%-63.05K | -27.39%944.81K | -72.83%287.84K |
-Change in payables and accrued expense | -16.07%1.38M | 74.94%2.13M | 20.72%1.95M | 6.78%4.97M | -70.58%497.66K | 61.13%1.64M | -35.28%1.22M | 2,324.45%1.62M | -42.49%4.66M | -61.32%1.69M |
-Change in other current liabilities | --0 | --0 | --124.48K | 148.24%1.45M | 148.58%1.45M | ---- | ---- | --0 | -5,348.14%-3M | -973.19%-2.98M |
Cash from discontinued investing activities | ||||||||||
Operating cash flow | -150.09%-66.65K | 81.50%-70.62K | 90.72%-32.32K | 97.46%-176.95K | 156.85%419.81K | 105.74%133.08K | -71.35%-381.63K | 90.56%-348.2K | 73.95%-6.97M | 78.89%-738.44K |
Investing cash flow | ||||||||||
Cash flow from continuing investing activities | 0 | 0 | 0 | -10,996.78%-1.58M | -307.28%-1.23M | -0.16%-147.94K | 60.03%-186.72K | -282.85%-9.75K | 99.87%-14.22K | 202.55%595.29K |
Net PPE purchase and sale | --0 | ---- | ---- | -1,423.60%-1.58M | -308.09%-1.24M | -228.57%-138.2K | ---- | ---- | 99.06%-103.59K | 166.87%597.63K |
Net other investing changes | ---- | ---- | ---- | ---- | ---- | ---- | ---- | -129.86%-9.75K | 121.21%89.37K | -100.83%-2.34K |
Cash from discontinued investing activities | ||||||||||
Investing cash flow | --0 | --0 | --0 | -10,996.78%-1.58M | -307.28%-1.23M | -0.16%-147.94K | 60.03%-186.72K | -282.85%-9.75K | 99.87%-14.22K | 202.55%595.29K |
Financing cash flow | ||||||||||
Cash flow from continuing financing activities | -103.43%-35K | -66.98%245.61K | 168.90%35K | -82.23%1.3M | -187.61%-475.07K | -56.70%1.02M | 175.84%743.78K | -99.76%13.02K | 13.38%7.32M | -85.23%542.24K |
Net issuance payments of debt | 85.54%-35K | -111.32%-57.6K | 168.90%35K | 120.07%97.22K | 31.09%-182.75K | -326.39%-242K | --508.96K | --13.02K | -107.63%-484.35K | -107.48%-265.2K |
Net common stock issuance | --0 | ---- | ---- | -86.98%1.25M | --0 | 38.44%1.25M | ---- | ---- | 124,671.29%9.63M | 26,996.57%2.09M |
Cash dividends paid | ---- | ---- | ---- | --0 | ---- | ---- | ---- | ---- | --0 | --0 |
Interest paid (cash flow from financing activities) | ---- | ---- | ---- | --0 | ---- | ---- | ---- | ---- | -50.86%-1.1M | 19.13%-153.98K |
Net other financing activities | --0 | ---- | ---- | 93.29%-48.49K | 74.11%-292.32K | -99.32%9K | ---- | ---- | 20.44%-722.87K | -222.93%-1.13M |
Cash from discontinued financing activities | ||||||||||
Financing cash flow | -103.43%-35K | -66.98%245.61K | 168.90%35K | -82.23%1.3M | -187.61%-475.07K | -56.70%1.02M | 175.84%743.78K | -99.76%13.02K | 13.38%7.32M | -85.23%542.24K |
Net cash flow | ||||||||||
Beginning cash position | -33.70%209.55K | -75.42%34.56K | -93.43%31.88K | 234.59%485.54K | 1,427.94%1.32M | 59.36%316.05K | -92.48%140.61K | 234.59%485.54K | -99.54%145.12K | -84.36%86.46K |
Current changes in cash | -110.12%-101.65K | -0.26%174.99K | 100.78%2.68K | -233.26%-453.67K | -423.02%-1.29M | 998.36%1M | 110.50%175.44K | -120.01%-344.93K | 101.08%340.43K | 197.91%399.09K |
End cash Position | -91.83%107.89K | -33.70%209.55K | -75.42%34.56K | -93.43%31.88K | -93.43%31.88K | 1,427.94%1.32M | 59.36%316.05K | -92.48%140.61K | 234.59%485.54K | 234.59%485.54K |
Free cash from | -1,201.58%-66.65K | 87.78%-70.62K | 90.72%-32.32K | 75.24%-1.76M | -485.05%-823.83K | 99.78%-5.12K | 35.15%-578.09K | 90.56%-348.2K | 81.34%-7.09M | 96.79%-140.81K |
Accounting Standards | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP |
Audit Opinions | -- | -- | -- | Unqualified Opinion with Explanatory Notes | -- | -- | -- | -- | Unqualified Opinion with Explanatory Notes | -- |
FY: Financial Year. Refers to the 10-K file disclosed by the listed company to the SEC.
Q: Quarter. Refers to the 10-Q file disclosed by the listed company to the SEC. Q1, Q2, Q3, and Q4 are quarterly reports each with a span of 3 months; Q6 and Q9 are cumulative reports, with Q6 including 6 months and Q9 9 months.